Galapagos could move up to 20% on figotinib decision, says Morgan Stanley » 17:1510/1910/19/20
Morgan Stanley analyst…
Story temporarily locked.
Galapagos price target lowered to EUR 125 from EUR 135 at UBS » 12:3910/1610/16/20
UBS analyst Laura…
UBS analyst Laura Sutcliffe lowered the firm's price target on Galapagos to EUR 125 from EUR 135 and keeps a Neutral rating on the shares.
Galapagos price target lowered to $131 from $135 at RBC Capital » 09:2410/1610/16/20
RBC Capital analyst Brian…
RBC Capital analyst Brian Abrahams lowered the firm's price target on Galapagos to $131 from $135 and keeps a Sector Perform rating on the shares. The analyst cites the company's announcement that its GLPG1972 failed to meet its endpoints in a phase 2 osteoarthritis study, showing no significant difference vs. placebo in any treatment group. Abrahams adds that the price target reduction is modest as he had ascribed only a "limited value to the asset given the challenging indication". However, as "setbacks accumulate", the analyst states that it is important for the upcoming datapoints to "regenerate enthusiasm" for Galapagos' long-term pipeline success.
Gilead investors may start questioning Galapagos collaboration, says Citi » 06:4410/1610/16/20
Citi analyst Mohit Bansal…
Citi analyst Mohit Bansal believes Gilead Sciences (GILD) investors may start questioning the collaboration with Galapagos (GLPG) after GLPG-1972 failed to show any difference versus placebo in improving knee cartilage thickness at 52-weeks. Gilead has opt-in rights for the U.S. rights to this program and was a key part of last year's new collaboration, Bansal tells investors in a research note. The analyst says that while GLPG-1972 was mentioned last year as a key catalyst for the Galapagos collaboration, he does not have this osteoarthritis asset in his model. Bansal keeps a Buy rating on Gilead with an $80 price target.
Servier, Galapagos announce ROCCELLA trial failed to meet primary objective » 16:2210/1510/15/20
Servier and Galapagos…
Servier and Galapagos report that no signal of activity was observed in the topline results in their ROCCELLA Phase 2 trial with GLPG1972/S201086. ROCCELLA is a global, double-blind, placebo-controlled, dose ranging trial evaluating the efficacy and safety of three different once-daily oral doses of GLPG1972/S201086 in 932 patients with knee osteoarthritis, or OA, over 52 weeks of treatment. The study population was aged between 40 to 76 years, mainly female and with a mean disease duration of 7 years. The primary objective of ROCCELLA was to demonstrate the efficacy of at least one dose of GLPG1972/S201086 compared to placebo after 52 weeks of treatment in reducing cartilage loss of the central medial tibiofemoral compartment of the target knee via quantitative MRI. The trial failed to meet the primary objective. The change from baseline to week 52 in cartilage thickness, in mm was -0.116 for the placebo group and -0.068, -0.097 and -0.085, for the low, medium and high dose, respectively. Statistically significant difference versus placebo was not reached in any of the treated groups.There was no significant difference compared to placebo observed on secondary endpoints, including clinical outcomes.Additional analyses are being conducted to fully evaluate the results, which will be presented at upcoming medical conferences. GLPG1972/S201086 was generally well-tolerated by patients in this Phase 2 trial.
Galapagos price target lowered to EUR 125 from EUR 140 at Barclays » 11:5810/1310/13/20
Barclays analyst Emily…
Barclays analyst Emily Field lowered the firm's price target on Galapagos to EUR 125 from EUR 140 and keeps an Equal Weight rating on the shares.
|Over a week ago|
Gilead and Galapagos present data on filgotinib for UC treatment at UEGW » 09:2310/1210/12/20
Gilead Sciences (GILD)…
Gilead Sciences (GILD) and Galapagos (GLPG) presented late-breaking data demonstrating sustained efficacy and safety with filgotinib, an investigational, oral, once-daily, JAK1 preferential inhibitor, for the treatment of moderately to severely active ulcerative colitis, UC. The data from the randomized, double-blind, placebo-controlled, Phase 2b/3 SELECTION trial showed that a significantly igher proportion of patients treated with filgotinib 200 mg, versus placebo, achieved clinical remission at Week 10 and maintained remission through Week 58. In addition, significantly more patients achieved six-month corticosteroid-free remission. The full results were presented at the 2020 United European Gastroenterology Week, UEGW, Virtual Meeting.
Gilead, Galapagos presents data from Phase 2b/3 trial of filgotinib » 09:2010/1210/12/20
Gilead Sciences (GILD)…
Gilead Sciences (GILD) and Galapagos (GLPG) presented late-breaking data demonstrating sustained efficacy and safety with filgotinib, an investigational, oral, once-daily, JAK1 preferential inhibitor, for the treatment of moderately to severely active ulcerative colitis. The data from the randomized, double-blind, placebo-controlled, Phase 2b/3 SELECTION trial showed that a significantly higher proportion of patients treated with filgotinib 200 mg, versus placebo, achieved clinical remission at Week 10 and maintained remission through Week 58. In addition, significantly more patients achieved six-month corticosteroid-free remission. The full results were presented today at the 2020 United European Gastroenterology Week Virtual Meeting. UC is a longer-term condition characterized by inflammation of the mucosal lining of the colon and rectum. An increasingly prevalent disease, UC has a significant impact on the quality of life of more than 2 million people around the world. Despite current treatments, many patients experience fecal urgency, incontinence, recurring bloody diarrhea, and the need to empty their bowels frequently, often accompanied by abdominal pain, poor sleep and fatigue. The SELECTION study included biologic-naive patients, for whom prior conventional therapy had failed, as well as biologic-experienced patients, a high proportion of whom had been non-responders to at least two different lines of prior biologics. In total, 43 percent of patients in the biologic-experienced cohort had failed treatment with both a TNF inhibitor and vedolizumab. The study allowed the enrollment of patients who were taking steroids, and/or immunomodulators, including methotrexate, mercaptopurine or azathioprine, as they would in real-world clinical practice. Overall, 1,348 biologic-naive or biologic-experienced adult patients with moderately to severely active UC were randomized and treated in the SELECTION study. Among biologic-naive patients treated with filgotinib 200 mg, a significantly higher proportion of patients achieved clinical remission at Week 10 compared with placebo. Additionally, a significantly higher proportion of biologic-naive patients treated with filgotinib 200 mg versus placebo achieved Mayo Clinic Score remission, endoscopic remission and histologic remission. A significantly higher proportion of biologic-experienced patients treated with filgotinib 200mg achieved clinical remission at Week 10 compared with placebo. Patients treated with filgotinib who achieved clinical response or remission at Week 10 were re-randomized to their induction dose of filgotinib or placebo in a 2:1 ratio and treated through Week 58. At Week 58, 37.2 percent of patients receiving filgotinib 200 mg achieved clinical remission, compared with 11.2 percent of patients treated with placebo. A significantly higher proportion of those treated with filgotinib 200 mg versus placebo achieved sustained clinical remission, MCS remission, endoscopic remission and histologic remission. Additionally, a significantly higher proportion of patients treated with filgotinib 200 mg achieved six-month corticosteroid-free clinical remission at Week 58 compared with placebo. Overall, the incidence of adverse events, serious AEs and discontinuations due to AEs were similar in the filgotinib and placebo groups in both the induction and maintenance periods of the study. Serious infections, herpes zoster, venous thrombosis, pulmonary embolism and gastrointestinal perforation were infrequent and comparable across treatment groups. The most common adverse events of interest in the induction trials were serious infections, herpes zoster, opportunistic infections and pulmonary embolism. In the maintenance trial, the most common adverse events of interest were serious infections, herpes zoster and venous thrombosis. Two deaths were observed in the filgotinib 200 mg treatment group in the maintenance trial; both adverse events leading to deaths were considered by the study investigators to be unrelated to study drug.
Galapagos price target raised to EUR 135 from EUR 130 at UBS » 12:0810/0810/08/20
UBS analyst Laura…
UBS analyst Laura Sutcliffe raised the firm's price target on Galapagos to EUR 135 from EUR 130 and keeps a Neutral rating on the shares.
Galapagos management to meet virtually with Cantor Fitzgerald » 04:5510/0710/07/20
Virtual Meeting to be…
Virtual Meeting to be held on October 7 hosted by Cantor Fitzgerald.